(Reuters) - German drugmaker Bayer said more joint ventures in India could be the way forward to tap into a growing market where rivals are willing to pay far higher premiums in takeover auctions. In January, Bayer signed an agreement with unlisted Indian pharmaceutical company Zydus Cadila to form a venture to jointly market pharmaceuticals. It did not disclose financial terms.
